Strides Pharma Science financials

·Pharma & HealthChart ›
Latest results Q2 FY27 · Jul–Sep 2026
Revenue
₹1,430cr+17.1% on Q2 FY26
Net profit
₹134cr+2.0% on Q2 FY26
EBITDA margin
17.6%−1.4 pts on Q2 FY26
EPS
₹14.19+2.5% on Q2 FY26

Quarterly results

Every quarter ›
₹ croreQ2 FY27Q2 FY26Change
Revenue1,4301,221+17.1%
EBITDA251232+8.4%
EBITDA margin17.6%19.0%−1.4 pts
Profit before tax150154−3.0%
Net profit134132+2.0%
EPS₹14.19₹13.84+2.5%

Over time

Q2 FY27 · Jul–Sep 2026latest
Revenue₹1,430 crNet profit₹134 crNet margin9.4%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
10,006————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
137189182267354
54.041.834.6−53.9−39.4
1,6691,6691,7962,4152,774
11,592————
5,2134,8594,5654,0513,688
—+6.4%+12.7%+9.8%—
956925803743430
18.3%19.0%17.6%18.4%11.7%
739723611523187
6375753,598−94.3−212
12.2%11.8%78.8%−2.3%−5.8%
₹66.92₹60.34₹389.86−₹7.66−₹21.98
—−84.5%+5,188.9%+65.2%—
—70368470144.4
—−423−242−118−94.9
280280442583−50.5
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

STAR₹1,085.60

Strides Pharma Science Ltd.

· Pharma & Health
₹ CrorePeersSPARCSUPRIYASHILPAMEDTHYROCARERUBICONVIYASHYATHARTHPARKHOSPSMcap ₹10,006 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————10,006.3
- Cash, Equiv & ST Investments354.3266.8182.1188.7137.3
+ Minority Interest-39.4-53.934.641.854.0
+ Total Debt2,774.52,414.51,795.61,668.71,668.7
Enterprise Value————11,591.7
Revenue3,688.44,051.14,565.34,858.75,213.3
Growth %, YoY—+9.8+12.7+6.4—
EBITDA430.2743.3802.8925.3956.3
Margin %11.6618.3517.5819.0418.34
EBIT186.9522.6610.6722.9738.9
Net Income-212.3-94.33,597.5574.5637.0
Margin %-5.76-2.3378.8011.8212.22
EPS, Adj (current shares)-21.98-7.66389.8660.3466.92
Growth %, YoY—+65.2+5,188.9-84.5—
Cash from Operations44.4701.1684.4702.5—
Capital Expenditures-94.9-118.2-242.5-422.9—
Free Cash Flow-50.5582.9441.9279.6279.6
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Strides Pharma Science financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Strides Pharma Science (NSE: STAR) had a market capitalisation of ₹10,116 crore at the 29 October 2026 close (₹1,097.50 a share), a PE ratio of 16.4 on the last four quarters' profit and a price-to-book ratio of 2.96. In FY26 its consolidated net profit attributable to shareholders was ₹556 crore on revenue of ₹4,859 crore; in Q2 FY27 (July–September 2026) it was ₹131 crore, up 2.6% year on year. Its debt-to-equity ratio was 0.53 on 30 September 2026. Promoters held 29.00% of the shares on 30 September 2026.

Share price used
₹1,097.50 · 29 October 2026 close
Latest balance sheet
30 September 2026
Shareholding pattern
30 September 2026

Strides Pharma Science at a glance · consolidated

Market cap
₹10,116 Crat ₹1,097.50 · 29 Oct close
PE ratio (last 4 quarters)
16.418.2 on FY26 profit
Price to book (PB)
2.96book value ₹370.66 a share
ROE (FY26)
19.7%−134.0 pts vs FY25ROCE 19.3%
Debt to equity
0.53net debt ₹1,700 Cr
Promoter holding
29.00%+1.1 pts vs 30 Jun 202630 September 2026
Dividend yield
0.46%₹5 a share in 12 months
Net worth
₹3,416 Cr+24.0% vs 30 Sep 202530 September 2026
Free cash flow (FY26)
₹280 Cr−36.7% vs FY25

Questions

What is the Strides Pharma Science PE ratio today?

Strides Pharma Science's PE ratio is 16.4 at the 29 October 2026 close (₹1,097.50 a share): a market capitalisation of ₹10,116 crore divided by consolidated net profit attributable to shareholders of ₹617 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit attributable to shareholders (₹556 crore) it is 18.2.

What is the Strides Pharma Science PB ratio (price to book value)?

Strides Pharma Science's price-to-book (PB) ratio is 2.96 at the 29 October 2026 close: a market capitalisation of ₹10,116 crore divided by shareholders' equity (book value) of ₹3,416 crore on 30 September 2026. That is a book value of ₹370.66 per share against a share price of ₹1,097.50.

What is the Strides Pharma Science ROE and ROCE?

In FY26, Strides Pharma Science's return on equity (ROE) was 19.7% and its return on capital employed (ROCE) was 19.3%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 153.7% and ROCE 19.0%.

What is the Strides Pharma Science market cap?

Strides Pharma Science's market capitalisation was ₹10,116 crore at the 29 October 2026 close: 9.22 crore shares at ₹1,097.50 each.

What is the Strides Pharma Science EPS?

Strides Pharma Science's basic earnings per share (EPS) were ₹60.34 in FY26, against ₹390.54 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹66.91.

What is the Strides Pharma Science dividend in 2026 and its record date?

In 2026, Strides Pharma Science has declared one dividend: ₹5 with record date 31 July 2026.

Is Strides Pharma Science debt free?

No. Strides Pharma Science had borrowings of ₹1,847 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.53. Its cash and current investments were ₹147 crore, so its net debt was ₹1,700 crore.

What is the Strides Pharma Science debt to equity ratio?

Strides Pharma Science's debt-to-equity ratio was 0.53 on 30 September 2026: borrowings of ₹1,847 crore against total equity of ₹3,470 crore. A year earlier, on 30 September 2025, it was 0.62.

What is the Strides Pharma Science net worth?

Strides Pharma Science's net worth — shareholders' equity in its consolidated balance sheet — was ₹3,416 crore on 30 September 2026, up 24.0% from ₹2,756 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹10,116 crore at the 29 October 2026 close.

What is the Strides Pharma Science book value per share?

Strides Pharma Science's book value per share was ₹370.66 on 30 September 2026: shareholders' equity of ₹3,416 crore divided by the 9.22 crore shares in issue, up 24.0% from ₹298.99 a year earlier. The share price at the 29 October 2026 close was ₹1,097.50.

What is the Strides Pharma Science dividend yield?

Strides Pharma Science's dividend yield is 0.46% at the 29 October 2026 close: dividends of ₹5 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹1,097.50. They were ₹5 on 31 July 2026.

What is the Strides Pharma Science promoter holding?

Promoters held 29.00% of Strides Pharma Science on 30 September 2026, up 1.09 percentage points from 27.91% the previous quarter and up 1.14 percentage points from 27.86% a year earlier, according to the shareholding pattern filed with NSE.

What is the Strides Pharma Science shareholding pattern?

On 30 September 2026, Strides Pharma Science's shares were held by promoters 29.00%, foreign portfolio investors (FII/FPI) 27.98%, domestic institutions (DII) 15.51% (including mutual funds at 10.31%) and retail and other non-institutional investors 27.51%. Over the year, FII holding was down 0.53 percentage points from 28.51% and DII holding was up 2.53 percentage points from 12.98%.

How does the Strides Pharma Science PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit attributable to shareholders, Strides Pharma Science's PE ratio is 18.2, the second highest of the three: Sun Pharma Advanced Research 3.8 and Shilpa Medicare 75.2, a peer average of 39.5. Each is the company's market capitalisation at that price divided by its FY26 net profit.

Strides Pharma Science vs Sun Pharma Advanced Research: how do they compare?

In FY26, Strides Pharma Science earned net profit attributable to shareholders of ₹556 crore on revenue of ₹4,859 crore, against ₹1,556 crore on ₹1,879 crore for Sun Pharma Advanced Research. Strides Pharma Science's operating margin was 14.9% (Sun Pharma Advanced Research 84.5%) and its return on equity 19.7% (Sun Pharma Advanced Research 277.4%). At the 29 October 2026 close, Strides Pharma Science's market capitalisation was ₹10,116 crore against ₹5,938 crore for Sun Pharma Advanced Research, and its PE ratio on FY26 profit 18.2 against 3.8.

What is the Strides Pharma Science free cash flow?

In FY26, Strides Pharma Science generated ₹703 crore of cash from operations and spent ₹423 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹280 crore. In FY25 it was ₹442 crore.

What are the Strides Pharma Science latest quarterly results?

Strides Pharma Science's latest results are for Q2 FY27 (July–September 2026), filed on 29 October 2026: consolidated net profit attributable to shareholders ₹131 crore, up 2.6% from ₹128 crore in Q2 FY26; revenue from operations ₹1,430 crore, up 17.1% year on year.

When are the Strides Pharma Science next results?

Strides Pharma Science has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.

What is the Strides Pharma Science revenue and profit in FY26?

In FY26 (April 2025–March 2026), Strides Pharma Science's consolidated net profit attributable to shareholders was ₹556 crore, down 84.5% from ₹3,593 crore in FY25, on revenue from operations of ₹4,859 crore (up 6.4%).

How does Strides Pharma Science compare with its peers?

On FY26 consolidated figures, against Sun Pharma Advanced Research and Shilpa Medicare: Strides Pharma Science's operating margin of 14.9% is the lowest of the three (Sun Pharma Advanced Research 84.5%, Shilpa Medicare 20.5%; peer average 52.5%); its return on equity of 19.7% is the second highest of the three (Sun Pharma Advanced Research 277.4%, Shilpa Medicare 9.8%; peer average 143.6%); its revenue growth over three years of 9.6% a year is the lowest of the three (Sun Pharma Advanced Research 96.0% a year, Shilpa Medicare 13.6% a year; peer average 54.8% a year).

Where do these Strides Pharma Science figures come from?

From Strides Pharma Science's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.